Overview

Treatment of Polydrug-Using Opiate Dependents During Withdrawal

Status:
Completed
Trial end date:
2003-11-01
Target enrollment:
0
Participant gender:
All
Summary
Managed detoxification is a first and necessary step prior to treatment and rehabilitation. Detoxification can be a major obstacle for some patients, and the availability of managed and safe withdrawal is a prerequisite for long-term treatment. In our clinical practice we have felt the need for a standardised and safe detoxification treatment regimen for our opioid addicts, as dependence on multiple drugs is so common. Objectives 1. To assess whether a novel standardised treatment regimen - Buprenorphine (BPN) combined with Valproate (VPA) - will result in fewer withdrawal symptoms during detoxification of opiate-polydrug users than the existing treatment regimen, i.e. Clonidine (CLN) combined with Carbamazepine (CBZ). 2. To determine whether there are differences in treatment retention between the BPN/VPA and the CLN/CBZ groups. 3. To assess differences in clinical side-effects and biochemical interactions between the two treatment regimens.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Sorlandet Hospital HF
Treatments:
Buprenorphine
Valproic Acid
Criteria
Inclusion Criteria:

- Polydrug dependency (at least opiate and benzodiazepine dependency)

Exclusion Criteria:

- No severe psychiatric illness

- No history of epilepsy seizures

- No pregnancy or breastfeeding

- Fertile women must use contraceptives